Skip to main content
Decision of National organisation of Medicines of Greece
Approval of Temporary Individual Access to Early Access to the Medicinal Product GLIOVAC in Greece.
CEO’s statement for 2018
12 month progress report 31/08/2017-31/09/2018
ERC has made significant progress over the past 12 months in moving our experimental vaccine Gliovac (also know as ERC1671) toward commercialization.
New production site in the Netherlands
ERC has opened a new additional production site in the Netherlands dedicated to GMP-based production of Gliovac/ERC1671 against glioblastoma brain cancer, as well as vaccines based on the same,...
Approval for open phase II study
ULB Belgium’s ethical commitee has approved the protocol for an open phase II study of standard treatments in combination
Interest to use our technology for other cancers
Based on the visibility of preliminary results for GBM, independent groups expressed their strong interest to use the technology for other cancers.
for more details.